SG11201810470XA - Lysine conjugated immunoglobulins - Google Patents
Lysine conjugated immunoglobulinsInfo
- Publication number
- SG11201810470XA SG11201810470XA SG11201810470XA SG11201810470XA SG11201810470XA SG 11201810470X A SG11201810470X A SG 11201810470XA SG 11201810470X A SG11201810470X A SG 11201810470XA SG 11201810470X A SG11201810470X A SG 11201810470XA SG 11201810470X A SG11201810470X A SG 11201810470XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- osaka
- pct
- applicant
- rule
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/02—Aminoacyltransferases (2.3.2)
- C12Y203/02013—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662348410P | 2016-06-10 | 2016-06-10 | |
| PCT/JP2017/021672 WO2017213267A1 (en) | 2016-06-10 | 2017-06-12 | Lysine conjugated immunoglobulins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810470XA true SG11201810470XA (en) | 2018-12-28 |
Family
ID=59315675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810470XA SG11201810470XA (en) | 2016-06-10 | 2017-06-12 | Lysine conjugated immunoglobulins |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10941431B2 (https=) |
| EP (1) | EP3468614A1 (https=) |
| JP (1) | JP7041077B2 (https=) |
| KR (1) | KR102538866B1 (https=) |
| CN (1) | CN109475642B (https=) |
| AU (1) | AU2017279352B2 (https=) |
| BR (1) | BR112018075253A2 (https=) |
| CA (1) | CA3026991A1 (https=) |
| CL (1) | CL2021003383A1 (https=) |
| CO (1) | CO2018013314A2 (https=) |
| IL (1) | IL263329B (https=) |
| JO (1) | JOP20180118A1 (https=) |
| MX (1) | MX419566B (https=) |
| MY (1) | MY202858A (https=) |
| NZ (1) | NZ748605A (https=) |
| PE (1) | PE20190340A1 (https=) |
| PH (1) | PH12018502594A1 (https=) |
| RU (2) | RU2021136863A (https=) |
| SG (1) | SG11201810470XA (https=) |
| UA (1) | UA126799C2 (https=) |
| WO (1) | WO2017213267A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA124622C2 (uk) | 2015-12-18 | 2021-10-20 | ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. | Кон'юговані імуноглобуліни з c-кінцевим лізином |
| MY202858A (en) | 2016-06-10 | 2024-05-25 | Eisai R&D Man Co Ltd | Lysine conjugated immunoglobulins |
| AU2020268684C1 (en) * | 2019-05-09 | 2026-04-02 | Merus B.V. | Variant domains for multimerizing proteins and separation thereof |
| GB201907093D0 (en) * | 2019-05-20 | 2019-07-03 | Ucl Business Plc | Antibody functionalisation |
| CN115335406B (zh) * | 2020-02-12 | 2026-01-30 | 伊莱利利公司 | 抗体或抗原-结合片段的结晶 |
| BR112022018452A2 (pt) * | 2020-03-25 | 2022-11-01 | Lilly Co Eli | Proteínas de ligação multiespecíficas e métodos de desenvolvimento das mesmas |
| JP7787101B2 (ja) | 2020-05-20 | 2025-12-16 | ヤンセン バイオテツク，インコーポレーテツド | グリコシル化Ｆｃドメインを含むタンパク質の部位特異的コンジュゲーションのための方法 |
| AU2021350011A1 (en) * | 2020-09-25 | 2023-05-11 | Epivax, Inc. | Retro-inverso regulatory t cell epitopes |
| AU2022333321A1 (en) * | 2021-08-27 | 2024-04-11 | Janssen Biotech, Inc. | Anti-psma antibodies and uses thereof |
| CN117164701A (zh) * | 2022-12-27 | 2023-12-05 | 优洛生物(上海)有限公司 | 一种经改造的抗体、其制备方法及其用途 |
| CN120813607A (zh) | 2023-02-28 | 2025-10-17 | 卫材R&D管理有限公司 | 抗psma抗体、缀合物和使用方法 |
| WO2024211135A2 (en) * | 2023-04-07 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Characterization of crosslinking sites in antibody-drug conjugates |
| CN119375471A (zh) * | 2023-07-26 | 2025-01-28 | 菲鹏生物股份有限公司 | 抗体和抗体缀合物及其用途 |
| TW202602943A (zh) | 2024-03-22 | 2026-01-16 | 日商衛材R&D企管股份有限公司 | 抗ｔｒｏｐ２抗體藥物偶聯物及使用方法 |
| CN120779021A (zh) * | 2024-04-08 | 2025-10-14 | 菲鹏生物股份有限公司 | 抗体缀合物及其用途 |
| WO2026044039A2 (en) | 2024-08-21 | 2026-02-26 | Eisai R&D Management Co., Ltd. | Anti-cd73 antibodies, conjugates, and methods of use |
| WO2026044149A2 (en) | 2024-08-21 | 2026-02-26 | Eisai R&D Management Co., Ltd. | Synthesis of drug-linker combinations for antibody-drug conjugates |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| ES2642214T3 (es) | 2004-01-21 | 2017-11-15 | Novo Nordisk Health Care Ag | Conjugación de péptidos mediante transglutaminasa |
| CA2813411C (en) * | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| WO2013176516A1 (ko) | 2012-05-24 | 2013-11-28 | 한화케미칼 주식회사 | 트랜스글루타미나아제를 이용하여 제조한 항체-약물 결합체 및 이의 용도 |
| EP3564259A3 (en) * | 2012-11-09 | 2020-02-12 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
| WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
| CN105517577A (zh) * | 2013-06-21 | 2016-04-20 | 先天制药公司 | 多肽的酶促偶联 |
| AU2014286990A1 (en) * | 2013-07-11 | 2016-02-11 | Novartis Ag | Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase |
| WO2015015448A2 (en) * | 2013-07-31 | 2015-02-05 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates |
| PT3134127T (pt) * | 2014-04-25 | 2020-04-09 | Rinat Neuroscience Corp | Conjugados de anticorpo-fármaco com alta carga de fármaco |
| UA124622C2 (uk) * | 2015-12-18 | 2021-10-20 | ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. | Кон'юговані імуноглобуліни з c-кінцевим лізином |
| MY202858A (en) | 2016-06-10 | 2024-05-25 | Eisai R&D Man Co Ltd | Lysine conjugated immunoglobulins |
-
2017
- 2017-06-12 MY MYPI2018002415A patent/MY202858A/en unknown
- 2017-06-12 PE PE2018003193A patent/PE20190340A1/es unknown
- 2017-06-12 AU AU2017279352A patent/AU2017279352B2/en active Active
- 2017-06-12 BR BR112018075253-3A patent/BR112018075253A2/pt unknown
- 2017-06-12 RU RU2021136863A patent/RU2021136863A/ru unknown
- 2017-06-12 MX MX2018015331A patent/MX419566B/es unknown
- 2017-06-12 CA CA3026991A patent/CA3026991A1/en active Pending
- 2017-06-12 UA UAA201900242A patent/UA126799C2/uk unknown
- 2017-06-12 SG SG11201810470XA patent/SG11201810470XA/en unknown
- 2017-06-12 NZ NZ748605A patent/NZ748605A/en unknown
- 2017-06-12 KR KR1020197000701A patent/KR102538866B1/ko active Active
- 2017-06-12 JP JP2018563925A patent/JP7041077B2/ja active Active
- 2017-06-12 EP EP17737890.8A patent/EP3468614A1/en active Pending
- 2017-06-12 WO PCT/JP2017/021672 patent/WO2017213267A1/en not_active Ceased
- 2017-06-12 CN CN201780043485.4A patent/CN109475642B/zh active Active
- 2017-06-12 RU RU2018145507A patent/RU2762939C2/ru active
- 2017-07-28 US US15/662,981 patent/US10941431B2/en active Active
-
2018
- 2018-11-27 IL IL263329A patent/IL263329B/en unknown
- 2018-12-07 CO CONC2018/0013314A patent/CO2018013314A2/es unknown
- 2018-12-09 JO JOP/2018/0118A patent/JOP20180118A1/ar unknown
- 2018-12-10 PH PH12018502594A patent/PH12018502594A1/en unknown
-
2021
- 2021-01-27 US US17/159,655 patent/US11753669B2/en active Active
- 2021-12-16 CL CL2021003383A patent/CL2021003383A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018145507A (ru) | 2020-07-10 |
| CL2021003383A1 (es) | 2022-08-19 |
| PH12018502594A1 (en) | 2019-10-14 |
| KR20190018159A (ko) | 2019-02-21 |
| IL263329B (en) | 2022-05-01 |
| JOP20180118A1 (ar) | 2019-01-30 |
| RU2762939C2 (ru) | 2021-12-24 |
| CN109475642A (zh) | 2019-03-15 |
| UA126799C2 (uk) | 2023-02-08 |
| WO2017213267A1 (en) | 2017-12-14 |
| JP2019525897A (ja) | 2019-09-12 |
| AU2017279352B2 (en) | 2024-07-25 |
| CO2018013314A2 (es) | 2019-02-19 |
| BR112018075253A2 (pt) | 2019-04-30 |
| RU2021136863A (ru) | 2022-02-01 |
| EP3468614A1 (en) | 2019-04-17 |
| NZ748605A (en) | 2023-05-26 |
| US20210171998A1 (en) | 2021-06-10 |
| PE20190340A1 (es) | 2019-03-07 |
| RU2018145507A3 (https=) | 2020-10-15 |
| MX2018015331A (es) | 2019-08-16 |
| US10941431B2 (en) | 2021-03-09 |
| US11753669B2 (en) | 2023-09-12 |
| IL263329A (en) | 2018-12-31 |
| KR102538866B1 (ko) | 2023-06-02 |
| MX419566B (es) | 2025-01-14 |
| JP7041077B2 (ja) | 2022-03-23 |
| MY202858A (en) | 2024-05-25 |
| AU2017279352A1 (en) | 2018-12-13 |
| CA3026991A1 (en) | 2017-12-14 |
| US20180044711A1 (en) | 2018-02-15 |
| CN109475642B (zh) | 2023-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810470XA (en) | Lysine conjugated immunoglobulins | |
| SG11201804856VA (en) | C-terminal lysine conjugated immunoglobulins | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201805532XA (en) | Multivalent and multispecific 41bb-binding fusion proteins | |
| SG11201806624XA (en) | Deposition of molybdenum thin films using a molybdenum carbonyl precursor | |
| SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| SG11201811338VA (en) | A novel botulinum neurotoxin and its derivatives | |
| SG11201809857TA (en) | Anti-CTLA-4 Antibodies | |
| SG11201900200XA (en) | Tgfb antibodies, methods, and uses | |
| SG11201809872TA (en) | Using hardware based secure isolated region to prevent piracy and cheating on electronic devices | |
| SG11201808821WA (en) | Agonistic antibodies that bind human cd40 and uses thereof | |
| SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201901307VA (en) | Heterodimeric immunoglobulin constructs and preparation methods thereof | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201810872UA (en) | Composition and method for reducing neutropenia | |
| SG11201807523PA (en) | Ilt7 binding molecules and methods of using the same | |
| SG11201810396QA (en) | Pegylated carfilzomib compounds | |
| SG11201908456VA (en) | Linker units and molecular constructs comprising same | |
| SG11201805001UA (en) | Method of treating influenza a |